US FDA's Biosimilar Advisory Committee Policy Evolves
If first-in-class biosimilar doesn't raise new scientific issues, it may not need advisory committee meeting, FDA's Christl says in interview with the Pink Sheet, suggesting a case-by-case approach going forward.
You may also be interested in...
US FDA Vaccines Adcomm May Be Called To Review COVID-19 Vaccine Strain Changes
CBER Director Peter Marks said the VRBPAC may need to opine on the immunogenicity data gathered for vaccine updates.
US FDA's Biosimilars Chief Leah Christl Plans Departure
A departure date has yet to be determined for the associate director of therapeutic biologics, who helped negotiate and implement the biosimilar user fee program.
Biosimilars: US FDA Expecting More Applications, Fewer Applicants
Preparing biosimilar applications still takes as much time as it would for an original BLA, FDA says.